Why radiopharmaceuticals are gaining ground in the fight against cancer
Drug Target Review
JUNE 6, 2025
RMX initiated the first IND for Lu-177 dotatate in the US for NETs at Excel Diagnostic Oncology Center, where we treated our first patient in August 2010,” he recalls. At the heart of radiopharmaceutical therapy is the ability to cause precise DNA damage within cancer cells, disrupting their ability to grow and divide.
Let's personalize your content